Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Norwegian Cancer Society | OTHER |
| Northern Health Authority | OTHER_GOV |
| St. Olavs Hospital | OTHER |
| Rigshospitalet, Denmark |
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to validate TNM-Immunoscore in resected non-small cell lung cancer.
The main aim is to validate the most promising T-cell marker candidates from earlier studies in a prospective multicenter study to establish a prognostic TNM-Immunoscore.
The investigators will include around 1000 stage I-IIIA patients from various centers in Scandinavia. The investigators will also collect demographic and clinicopathological data, blood and tissues in a database and biobank. Candidate T-cell markers will be analyzed by immunohistochemistry for validation and by other methods for exploration of their impact on prognosis
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| NSCLC patients | Resected NSCLC patients with curative intent |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Will look for immune infiltration | Other |
|
| Measure | Description | Time Frame |
|---|---|---|
| Overall survival | Overall survival in the 1) overall population and in the 2) squamous cell carcinoma and 3) adenocarcinoma subgroups. | 5 year follow-up |
| Measure | Description | Time Frame |
|---|---|---|
| TTR | Time to recurrence in the 1) overall population and in the 2) squamous cell carcinoma and 3) adenocarcinoma subgroups. | 5 year follow-up |
| Disease-specific survival | Disease specific survival in the 1) overall population and in the 2) squamous cell carcinoma and 3) adenocarcinoma subgroups. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Pasients coming for resection of primary NSCLC with a curative intent
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Lill-Tove R Busund, MD, PhD | University Hospital of North Norway | Principal Investigator |
| Sigve Andersen, MD,PhD | University Hospital of North Norway | Principal Investigator |
| Tom Dønnem, MD,PhD | University Hospital of North Norway | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Rigshospitalet | Copenhagen | København Ø | 2100 | Denmark | ||
| Odense Universitetshospital |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 26578726 | Background | Donnem T, Kilvaer TK, Andersen S, Richardsen E, Paulsen EE, Hald SM, Al-Saad S, Brustugun OT, Helland A, Lund-Iversen M, Solberg S, Gronberg BH, Wahl SG, Helgeland L, Flotten O, Pohl M, Al-Shibli K, Sandanger TM, Pezzella F, Busund LT, Bremnes RM. Strategies for clinical implementation of TNM-Immunoscore in resected nonsmall-cell lung cancer. Ann Oncol. 2016 Feb;27(2):225-32. doi: 10.1093/annonc/mdv560. Epub 2015 Nov 16. | |
| 37100205 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D002289 | Carcinoma, Non-Small-Cell Lung |
| ID | Term |
|---|---|
| D002283 | Carcinoma, Bronchogenic |
| D001984 | Bronchial Neoplasms |
| D008175 | Lung Neoplasms |
| D012142 | Respiratory Tract Neoplasms |
Not provided
Not provided
| OTHER |
| Odense University Hospital | OTHER |
| Oslo University Hospital | OTHER |
| University of Tromso | OTHER |
Not provided
Not provided
Not provided
Tumor specimen Blood
| 5 year follow-up |
| Odense |
| 5000 |
| Denmark |
| Oslo University Hospital | Oslo | 0379 | Norway |
| University Hospital of North Norway | Tromsø | 9038 | Norway |
| St.Olav Hospital, University Hospital of Trondheim | Trondheim | 7006 | Norway |
| Result |
| Rakaee M, Andersen S, Giannikou K, Paulsen EE, Kilvaer TK, Busund LR, Berg T, Richardsen E, Lombardi AP, Adib E, Pedersen MI, Tafavvoghi M, Wahl SGF, Petersen RH, Bondgaard AL, Yde CW, Baudet C, Licht P, Lund-Iversen M, Gronberg BH, Fjellbirkeland L, Helland A, Pohl M, Kwiatkowski DJ, Donnem T. Machine learning-based immune phenotypes correlate with STK11/KEAP1 co-mutations and prognosis in resectable NSCLC: a sub-study of the TNM-I trial. Ann Oncol. 2023 Jul;34(7):578-588. doi: 10.1016/j.annonc.2023.04.005. Epub 2023 Apr 24. |
| D013899 |
| Thoracic Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |